<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Uremic platelet dysfunction</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Uremic platelet dysfunction</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Uremic platelet dysfunction</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey S Berns, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas A Golper, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H397868534"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The association between kidney dysfunction and bleeding was first recognized in the mid-1700s [<a href="#rid1">1,2</a>]. However, the mechanisms underlying this association remain incompletely understood. Impaired platelet function is one of the main determinants of abnormal bleeding in patients with a low glomerular filtration rate (GFR). </p><p>Although often referred to as "uremic bleeding," bleeding in this setting generally occurs in patients who do not have clinical symptoms or signs of uremia. As such, the term "uremic" in many studies discussed herein is a misnomer when used to describe patients undergoing regular maintenance dialysis or patients with advanced chronic kidney disease (CKD) who do not yet require dialysis. </p><p>This topic reviews treatment and prevention of bleeding in patients with severely decreased GFR. Separate topics discuss:</p><p class="bulletIndent1"><span class="glyph">●</span>Thrombosis risk with impaired kidney function. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Venous thromboembolism (see  <a class="medical medical_review" href="/z/d/html/1361.html" rel="external">"Overview of the causes of venous thrombosis", section on 'Renal diseases'</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Arterial thrombosis (see  <a class="medical medical_review" href="/z/d/html/7190.html" rel="external">"Chronic kidney disease and coronary heart disease"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other causes of platelet dysfunction.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Liver disease (see  <a class="medical medical_review" href="/z/d/html/13932.html" rel="external">"Hemostatic abnormalities in patients with liver disease"</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Von Willebrand disease (see  <a class="medical medical_review" href="/z/d/html/1307.html" rel="external">"Clinical presentation and diagnosis of von Willebrand disease"</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Hereditary platelet disorders (see  <a class="medical medical_review" href="/z/d/html/6675.html" rel="external">"Inherited platelet function disorders (IPFDs)"</a>)</p><p class="bulletIndent2"><span class="glyph">•</span>Cause unknown (see  <a class="medical medical_review" href="/z/d/html/1367.html" rel="external">"Approach to the adult with a suspected bleeding disorder"</a>)</p><p></p><p class="headingAnchor" id="H73411787"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Bleeding associated with kidney disease can have many causes. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Platelet dysfunction</strong> – Platelet dysfunction is thought to be the main determinant of abnormal bleeding in patients with reduced glomerular filtration rate (GFR).</p><p></p><p class="bulletIndent1">The cause of impaired platelet function in patients with low GFR is incompletely understood. Reduced activation of integrin alpha IIb/beta3 (previously called glycoprotein IIb/IIIa), which serves as a receptor for fibrinogen, has been implicated in several in vitro studies [<a href="#rid3">3-5</a>]. Platelet granule dysfunction (storage pool disorder) has also been observed [<a href="#rid6">6,7</a>]. In contrast, von Willebrand factor levels and function, including interactions with platelets, appear to be normal [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/z/d/html/6683.html" rel="external">"Platelet biology and mechanism of anti-platelet drugs"</a>.)</p><p></p><p class="bulletIndent1">A role for increased nitric oxide (NO) in platelet dysfunction also has been suggested. The mechanism by which estrogens may reduce bleeding in some patients with severely decreased GFR is not well understood but may involve lowering L-arginine, which is a precursor for NO [<a href="#rid8">8</a>]. (See <a class="local">'Chronic refractory GI bleeding: Estrogens'</a> below.)</p><p></p><p class="bulletIndent1">Studies in which normal platelets were mixed with "uremic" plasma and vice versa suggest that a humoral (circulating) factor is responsible for the platelet dysfunction [<a href="#rid9">9</a>]. However, the specific factor(s) responsible have not been identified. Contributions of several molecules have been proposed, including urea, creatinine, phenol, phenolic acid, and guanidinosuccinic acid [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anemia </strong>– Anemia is common in chronic kidney disease (CKD). Anemia by any mechanism may reduce platelet interactions with endothelial cells; conversely, a hematocrit &gt;30 percent is thought to improve platelet binding to vessel walls by a rheologic mechanism. When red blood cells (RBCs) occupy a greater portion of the vessel lumen, platelets are pushed towards the vessel wall in a skimming layer at the endothelial surface. This close proximity allows the platelets to adhere to the endothelium more efficiently at sites of injury. </p><p></p><p class="bulletIndent1">Small studies have demonstrated that individuals with CKD treated with erythropoietin to increase their hematocrit had shortening of bleeding times and improved platelet binding to endothelial cells [<a href="#rid10">10,11</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Medications</strong> – Many patients with CKD have comorbidities treated with anticoagulant or antiplatelet medications. These agents, and/or heparin administered during routine hemodialysis, may contribute to increased bleeding risk.</p><p></p><p class="bulletIndent1">Patients with severely reduced GFR may display increased bleeding sensitivity to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>; a transient, cyclooxygenase-independent prolongation of the bleeding time following use of aspirin was greater in individuals with CKD than in individuals without CKD [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dialysis </strong>– Although dialysis may improve hemostasis by removing toxins that inhibit platelet function, hemodialysis may contribute to bleeding risk due to heparin use [<a href="#rid7">7</a>]. Studies evaluating dialysis as a means of reducing bleeding in patients with severely decreased GFR have been limited by small sample size and lack of assessment of clinically important outcomes [<a href="#rid13">13</a>].</p><p></p><p>In contrast to platelet dysfunction, levels of prohemostatic clotting factors are generally normal or increased in CKD. Reduced levels of the natural anticoagulants protein S and protein C that occur in nephrotic syndrome increase the risk of thrombosis rather than bleeding [<a href="#rid14">14</a>]. </p><p>The main interventions to reduce bleeding risk in patients with low GFR include optimizing dialysis, treating anemia, and monitoring medications that affect hemostasis. (See <a class="local">'Prevention of bleeding'</a> below.)</p><p class="headingAnchor" id="H2489978027"><span class="h1">ASSESSMENT OF BLEEDING RISK</span><span class="headingEndMark"> — </span>Bleeding associated with reduced glomerular filtration rate (GFR) can occur in patients with chronic kidney disease (CKD) on dialysis, patients with CKD not undergoing dialysis, and patients with acute kidney injury. Over time, with advances in the management of CKD and the treatment of anemia, concerns about bleeding due to kidney function impairment have decreased. Nevertheless, impaired kidney function remains a risk factor for bleeding, as indicated by most bleeding risk scores. (See  <a class="medical medical_review" href="/z/d/html/119889.html" rel="external">"Risks and prevention of bleeding with oral anticoagulants", section on 'Bleeding risk scores'</a>.)</p><p>There is no readily available and reliable assay to determine the magnitude of platelet dysfunction or the risk of bleeding in individuals with reduced GFR. The bleeding time, used in many early studies, is a poor surrogate for clinical bleeding and is rarely performed due to labor intensity and operator-dependence (see  <a class="medical medical_review" href="/z/d/html/4433.html" rel="external">"Platelet function testing", section on 'Tests not commonly used'</a>). Studies using the bleeding time as a surrogate for bleeding risk have found little correlation between the degree of kidney function impairment and the magnitude of platelet dysfunction [<a href="#rid15">15</a>]. </p><p>There is no specific cutoff for blood urea nitrogen (BUN) or serum creatinine that separates higher from lower bleeding risk. We consider patients who meet any of the following criteria to be at high risk for uremic platelet dysfunction:</p><p class="bulletIndent1"><span class="glyph">●</span>On dialysis</p><p class="bulletIndent1"><span class="glyph">●</span>Estimated GFR (eGFR) &lt;15 mL/min/1.73 m<sup>2</sup></p><p class="bulletIndent1"><span class="glyph">●</span>Oligoanuric acute kidney injury</p><p></p><p>However, individuals with eGFR &lt;30 mL/min/1.73 m<sup>2</sup> and even &lt;60 mL/min/1.73 m<sup>2</sup> may be at greater risk than individuals without kidney function impairment, and patients with reduced GFR often have comorbidities and/or take medications that increase bleeding risk  (<a class="graphic graphic_table graphicRef120264" href="/z/d/graphic/120264.html" rel="external">table 1</a>).</p><p>Observational studies report that bleeding risk is correlated with reduced eGFR [<a href="#rid16">16,17</a>]. For example, in a study including over 500,000 adults, the adjusted relative risk (aRR) of bleeding increased with lower eGFR as follows [<a href="#rid16">16</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>eGFR 60 to 90 – aRR 1.0 (95% CI 0.9 to 1.1)</p><p class="bulletIndent1"><span class="glyph">●</span>eGFR 45 to 60 – aRR 1.4 (95% CI 1.2 to 1.6)</p><p class="bulletIndent1"><span class="glyph">●</span>eGFR 30 to 45 – aRR 1.7 (95% CI 1.5 to 2.0)</p><p class="bulletIndent1"><span class="glyph">●</span>eGFR 15 to 30 – aRR 1.9 (95% CI 1.5 to 2.4)</p><p class="bulletIndent1"><span class="glyph">●</span>eGFR &lt;15 – aRR 3.0 (95% CI 1.3 to 6.6)</p><p></p><p>The aRRs above applied to individuals with urinary albumin-to-creatinine ratio &lt;30 mg/g; similar correlations and greater risks were seen for higher levels of albuminuria [<a href="#rid16">16</a>].</p><p>An earlier study involving &gt;11,000 older adults (&gt;65 years) reported an incidence of major hemorrhage within the first three years of starting dialysis of 14 percent (approximately 1 in 7) [<a href="#rid18">18</a>]. </p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H3965513033"><span class="h2">Typical sites of bleeding</span><span class="headingEndMark"> — </span>Platelet dysfunction in patients with severely decreased glomerular filtration rate (GFR) may manifest as abnormal bleeding involving the skin, resulting in easy bruising; the oral and nasal mucosa; gastrointestinal (GI) and urinary tracts; central nervous system; and respiratory system. Excessive bleeding may also occur in response to injury or invasive procedures [<a href="#rid19">19-21</a>]. </p><p>In a 2022 case-control study including nearly 6000 participants, individuals with stage 1 through 5 chronic kidney disease (CKD) were almost twice as likely to have an intracerebral hemorrhage as individuals without CKD (odds ratio 1.95, 95% CI 1.35-2.89) [<a href="#rid22">22</a>].</p><p>In a series of &gt;11,000 older adults starting dialysis, sites of bleeding included [<a href="#rid18">18</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Lower GI tract – 9 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Upper GI tract – 6 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Intracerebral – 1 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Subarachnoid – 0.1 percent</p><p></p><p class="headingAnchor" id="H3389440001"><span class="h2">Laboratory findings</span><span class="headingEndMark"> — </span>There is no readily available assay that indicates bleeding is due to reduced GFR rather than another cause. </p><p>Platelet count, prothrombin time (PT), and activated partial thromboplastin time (aPTT) are generally unaffected by CKD. If a patient with reduced GFR has thrombocytopenia or prolonged PT and/or aPTT, the cause of the abnormality should be evaluated and addressed. (See  <a class="medical medical_review" href="/z/d/html/6680.html" rel="external">"Diagnostic approach to thrombocytopenia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1368.html" rel="external">"Clinical use of coagulation tests", section on 'Evaluation of abnormal results'</a>.)</p><p>Some tests of platelet function are abnormal in individuals with reduced GFR, but these typically are not part of the evaluation, and their clinical relevance is unclear:</p><p class="bulletIndent1"><span class="glyph">●</span>Platelet aggregometry – Aggregometry is the gold standard test for platelet dysfunction, but it is generally used by hematologists to determine the cause of platelet dysfunction when standard evaluations have been unrevealing. Platelet aggregometry and related assays have shown a mixture of abnormalities in individuals with reduced GFR (reduced or increased platelet aggregation, depending on the agonist) [<a href="#rid23">23-28</a>]. Indications for platelet aggregometry are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4433.html" rel="external">"Platelet function testing", section on 'Uses of aggregometry'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bleeding time<strong> </strong>– Bleeding time is mostly of historical interest. It was commonly used in the past as a surrogate for bleeding risk, and many of the studies evaluating the pathogenesis of uremic platelet dysfunction observed prolonged bleeding times in many patients with reduced GFR [<a href="#rid15">15</a>]. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1">However, there are no data that unequivocally demonstrate associations between prolonged bleeding time and an increased risk of either spontaneous or postprocedure bleeding among patients with CKD. The bleeding time is rarely performed due to poor standardization, accuracy, and reproducibility. (See  <a class="medical medical_review" href="/z/d/html/4433.html" rel="external">"Platelet function testing", section on 'Tests not commonly used'</a>.)</p><p></p><p class="headingAnchor" id="H3004075890"><span class="h1">TREATMENT OF BLEEDING</span></p><p class="headingAnchor" id="H1833023799"><span class="h2">Identify and treat bleeding source and comorbidities</span><span class="headingEndMark"> — </span>As with any patient who has an active bleed, the primary goal is to identify and treat the source of blood loss. </p><p>Comorbidities and medication-induced changes that may be contributing to bleeding should be evaluated and treated, such as:</p><p class="bulletIndent1"><span class="glyph">●</span>Disseminated intravascular coagulation (DIC) (see  <a class="medical medical_review" href="/z/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For gastrointestinal (GI) bleeding, lesions such as ulcers, gastritis, angiodysplasia, or polyps (see  <a class="medical medical_review" href="/z/d/html/2548.html" rel="external">"Approach to acute upper gastrointestinal bleeding in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2547.html" rel="external">"Approach to acute lower gastrointestinal bleeding in adults"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For postoperative bleeding, an anatomic or pathologic cause of bleeding </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thrombocytopenia (see  <a class="medical medical_review" href="/z/d/html/6680.html" rel="external">"Diagnostic approach to thrombocytopenia in adults", section on 'Thrombocytopenic emergencies requiring immediate action'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anticoagulation (see  <a class="medical medical_review" href="/z/d/html/1325.html" rel="external">"Reversal of anticoagulation in intracranial hemorrhage"</a> and  <a class="medical medical_review" href="/z/d/html/1324.html" rel="external">"Management of warfarin-associated bleeding or supratherapeutic INR"</a> and  <a class="medical medical_review" href="/z/d/html/94788.html" rel="external">"Management of bleeding in patients receiving direct oral anticoagulants"</a> and  <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects", section on 'Bleeding'</a>)</p><p></p><p class="headingAnchor" id="H550495518"><span class="h2">Acute life-threatening bleeding</span><span class="headingEndMark"> — </span>We do not routinely treat uremic platelet dysfunction in patients who are bleeding. However, in patients with severely reduced glomerular filtration rate (GFR) who are experiencing acute life-threatening bleeding, potential hemostatic therapies include <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">desmopressin</a> (DDAVP), platelet transfusions, and Cryoprecipitate. There is no high-quality evidence demonstrating that these therapies have clinical benefit, but they have a theoretical rationale and may be the only interventions available after causes of bleeding other than kidney function impairment are addressed. (See <a class="local">'Identify and treat bleeding source and comorbidities'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>DDAVP</strong> – We generally do not use DDAVP to treat bleeding in patients with uremic platelet dysfunction. However, other UpToDate contributors administer DDAVP to patients with reduced GFR who have major bleeding, particularly in the surgical setting. (See <a class="local">'Details of DDAVP administration'</a> below and  <a class="medical medical_review" href="/z/d/html/94254.html" rel="external">"Anesthesia for dialysis patients", section on 'Management of bleeding'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Platelet transfusion</strong> – We do not routinely use platelet transfusion to treat bleeding in patients with reduced GFR, since it is likely that transfused platelets rapidly acquire the same uremic defect as native ones. However, some experts administer platelet transfusions in addition to DDAVP to a patient on maintenance dialysis who has uncontrolled bleeding. (See  <a class="medical medical_review" href="/z/d/html/94254.html" rel="external">"Anesthesia for dialysis patients", section on 'Management of bleeding'</a> and  <a class="medical medical_review" href="/z/d/html/7918.html" rel="external">"Platelet transfusion: Indications, ordering, and associated risks", section on 'Ordering platelets'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cryoprecipitate – </strong>Cryoprecipitate is rarely used to treat bleeding in patients with uremic platelet dysfunction although it is still included in some transfusion protocols. If used, Cryoprecipitate would generally be reserved for patients with severe bleeding for which another cause cannot be identified, especially if they have low or borderline fibrinogen levels. The dose is 10 units, given every 12 to 24 hours (more frequently for hypofibrinogenemia, in which case dosing is titrated to plasma fibrinogen level). (See  <a class="medical medical_review" href="/z/d/html/7943.html" rel="external">"Cryoprecipitate and fibrinogen concentrate", section on 'Uremic bleeding'</a>.)</p><p></p><p class="bulletIndent1">Evidence for Cryoprecipitate is limited. In a study of six patients with reduced GFR, it was thought to help control a major bleeding episode in four and shortened the bleeding time in all six [<a href="#rid29">29</a>]. Subsequent small studies have not shown consistent reductions in bleeding time or clinical bleeding [<a href="#rid30">30</a>].</p><p></p><p class="headingAnchor" id="H3945389653"><span class="h2">Chronic refractory GI bleeding: Estrogens</span><span class="headingEndMark"> — </span>Rarely, estrogen has been used for patients on maintenance hemodialysis who have chronic gastrointestinal (GI) tract bleeding due to angiodysplasia not amenable to other treatment. However, clinical experience is limited, and randomized trials are lacking. (See  <a class="medical medical_review" href="/z/d/html/1897.html" rel="external">"Unique aspects of gastrointestinal disease in patients on dialysis", section on 'Angiodysplasia'</a>.)</p><p>If used, reasonable doses of conjugated estrogens include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intravenous</strong> – 0.6 mg/kg daily for five days</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral</strong> – 25 to 50 mg orally per day</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transdermal </strong>– 50 to 100 mcg of transdermal <a class="drug drug_general" data-topicid="9422" href="/z/d/drug information/9422.html" rel="external">estradiol</a> twice weekly</p><p></p><p>The intravenous route is preferred due to greater study, but oral and transdermal routes may be more practical [<a href="#rid13">13,31-33</a>].</p><p>Most studies of estrogen therapy to treat GI bleeding in patients with reduced GFR have been of limited duration (five to seven days). Longer-term use may be limited by estrogen-related side effects. However, it is possible that compounds with weaker estrogenic activity and fewer side effects may be used successfully for longer periods of time [<a href="#rid34">34</a>]. Onset of action is within one day, with peak control reached over five to seven days and continued activity one week or more after therapy has been discontinued [<a href="#rid31">31-33</a>]. </p><p>Estrogens have been reported to control GI bleeding in case series of patients with severely reduced GFR, most of whom were undergoing maintenance hemodialysis [<a href="#rid31">31-36</a>]. </p><p>Other interventions for GI angiodysplasia are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/109902.html" rel="external">"Hereditary hemorrhagic telangiectasia (HHT): Evaluation and therapy for specific vascular lesions", section on 'Gastrointestinal lesions'</a>.)</p><p class="headingAnchor" id="H2554877610"><span class="h1">PREVENTION OF BLEEDING</span></p><p class="headingAnchor" id="H1757250784"><span class="h2">Spontaneous bleeding</span><span class="headingEndMark"> — </span>To reduce the risk of spontaneous bleeding in patients at high risk for uremic platelet dysfunction, we optimize routine chronic kidney disease (CKD) care. (See <a class="local">'Assessment of bleeding risk'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Optimize dialysis regimen and treat anemia</strong> – The principal ways of reducing spontaneous bleeding risk in a patient with severely reduced glomerular filtration rate (GFR) are to optimize the dialysis regimen (if the patient is on dialysis) and to treat anemia. (See  <a class="medical medical_review" href="/z/d/html/1836.html" rel="external">"Prescribing and assessing adequate hemodialysis"</a> and  <a class="medical medical_review" href="/z/d/html/1968.html" rel="external">"Prescribing peritoneal dialysis"</a>.)</p><p></p><p class="bulletIndent1">If anemia is present in a patient with reduced GFR, we evaluate for underlying cause(s) and treat as appropriate. Individuals with CKD can have more than one cause of anemia, and anemia should not be attributed solely to CKD without reviewing other possible contributing factors. (See  <a class="medical medical_review" href="/z/d/html/7133.html" rel="external">"Diagnostic approach to anemia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7149.html" rel="external">"Anemia of chronic disease/anemia of inflammation"</a>.)</p><p></p><p class="bulletIndent1">If the hemoglobin is &lt;10 g/dL due to CKD, we use an erythropoiesis-stimulating agent (ESA) to raise the hemoglobin to ≥10 g/dL (hematocrit ≥30 percent). Iron also may be indicated. Details are presented separately. (See  <a class="medical medical_review" href="/z/d/html/1952.html" rel="external">"Treatment of anemia in nondialysis chronic kidney disease", section on 'Treatment'</a> and  <a class="medical medical_review" href="/z/d/html/1926.html" rel="external">"Treatment of anemia in patients on dialysis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Judicious use of anticoagulation and antiplatelet agents</strong> – Anticoagulation or antiplatelet therapy should be used if needed, but anticoagulant dose reduction may be appropriate in some individuals with reduced GFR; details are presented separately. (See  <a class="medical medical_review" href="/z/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects", section on 'Chronic kidney disease'</a>.) </p><p></p><p class="bulletIndent1">We generally advise patients to avoid antiplatelet agents (<a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and nonsteroidal antiinflammatory drugs) for fever or routine aches and pains, especially when alternative such as <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> are available. </p><p></p><p class="bulletIndent1">However, patients taking antiplatelet agents for prevention of cardiovascular disease or other indications may reasonably continue them after reviewing the risk-benefit balance. (See  <a class="medical medical_review" href="/z/d/html/7573.html" rel="external">"Overview of primary prevention of cardiovascular disease"</a> and  <a class="medical medical_review" href="/z/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"</a>.)</p><p></p><p class="headingAnchor" id="H97144406"><span class="h2">Invasive procedures</span><span class="headingEndMark"> — </span>Options that may reduce bleeding risk in patients with severely decreased GFR who are undergoing a high-risk invasive procedure  (<a class="graphic graphic_table graphicRef86929" href="/z/d/graphic/86929.html" rel="external">table 2</a>) include identification of other bleeding risks, therapy for anemia, <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">desmopressin</a> (DDAVP), and dialysis. </p><p class="headingAnchor" id="H1678926429"><span class="h3">Identify other bleeding risks</span><span class="headingEndMark"> — </span>The patient history and laboratory testing for other hemostatic abnormalities may identify the need for specific therapies, such as a reversal agent for anticoagulation or treatment of a clotting factor deficiency. (See  <a class="medical medical_review" href="/z/d/html/94347.html" rel="external">"Perioperative blood management: Strategies to minimize transfusions", section on 'Systemic hemostatic agents'</a>.)</p><p class="headingAnchor" id="H1981958435"><span class="h3">Treatment of anemia</span><span class="headingEndMark"> — </span>To help prevent bleeding in patients with severely decreased GFR who are undergoing a high-risk invasive procedure, therapy for anemia (if present) should be attempted as feasible. No high-quality data have shown that risk of bleeding is ameliorated with treatment of anemia, but raising the hemoglobin to approximately 10 g/dL may reduce the bleeding time, occasionally to a normal level, in some patients [<a href="#rid11">11,37</a>].</p><p>Our approach to anemia depends on whether the procedure is elective or urgent, on the degree of anemia, and whether the patient may be eligible for future kidney transplant: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elective procedures</strong> – For patients who are planning to undergo nonurgent, elective, high-risk invasive procedures, the hemoglobin is raised to approximately 10 g/dL with a recombinant ESA and/or iron if needed [<a href="#rid11">11,13</a>]. (See  <a class="medical medical_review" href="/z/d/html/1952.html" rel="external">"Treatment of anemia in nondialysis chronic kidney disease", section on 'Treatment'</a> and  <a class="medical medical_review" href="/z/d/html/1926.html" rel="external">"Treatment of anemia in patients on dialysis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Urgent procedures</strong> – Use of an ESA and/or iron is not an option for patients undergoing urgent procedures because these therapies take weeks to be effective. For patients at high risk for uremic platelet dysfunction (see <a class="local">'Assessment of bleeding risk'</a> above) who are undergoing an urgent high-risk invasive procedure, are not planning to pursue kidney transplant, and have hemoglobin &lt;9 g/dL, we suggest red blood cell (RBC) transfusion targeted to raise the hemoglobin level to approximately 10 g/dL. </p><p></p><p>We <strong>avoid</strong> RBC transfusions to prevent uremic bleeding in patients with CKD who are potential kidney transplant candidates because of the risk of allosensitization. We do not avoid RBC transfusion in potential kidney transplant candidates who have severe anemia or rapidly falling hemoglobin; indications for RBC transfusion in such patients are the same as those for the general population. (See  <a class="medical medical_review" href="/z/d/html/7948.html" rel="external">"Indications and hemoglobin thresholds for RBC transfusion in adults", section on 'Symptomatic patient'</a>.)</p><p>Raising the hemoglobin to approximately 10 g/dL may reduce the bleeding time in some patients, but improvements in clinically important outcomes have not been demonstrated [<a href="#rid37">37</a>]. </p><p class="headingAnchor" id="H3807246572"><span class="h3">Other measures</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>DDAVP</strong> – The use of DDAVP to prevent uremic bleeding before, during, or after an invasive procedure is controversial. Some experts use DDAVP preoperatively or prior to an invasive procedure in patients on chronic dialysis who have a history of excessive bleeding or who are not optimally dialyzed before surgery [<a href="#rid38">38-40</a>]. (See <a class="local">'Details of DDAVP administration'</a> below and  <a class="medical medical_review" href="/z/d/html/1899.html" rel="external">"Medical management of the dialysis patient undergoing surgery", section on 'Uremic bleeding'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dialysis</strong> – We generally do not initiate dialysis before an invasive procedure solely to reduce bleeding risk, nor do we augment or intensify an existing dialysis prescription. However, if feasible, dialysis may be initiated in patients with severely reduced GFR who are planning to start dialysis, or dialysis may be intensified in patients who are inadequately dialyzed, prior to an elective procedure. </p><p></p><p class="bulletIndent1">Hemodialysis or peritoneal dialysis can partially correct the bleeding time and other in vitro tests of platelet function in patients with severely reduced GFR [<a href="#rid41">41-43</a>]; however, it is unknown whether either dialysis modality actually decreases the risk of major bleeding. </p><p></p><p class="bulletIndent1">If hemodialysis is performed immediately before or on the day of a high-risk invasive procedure, systemic anticoagulation should be avoided [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/z/d/html/1840.html" rel="external">"Anticoagulation for the hemodialysis procedure"</a>.)</p><p></p><p class="headingAnchor" id="H2818752697"><span class="h1">DETAILS OF DDAVP ADMINISTRATION</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potential indications </strong>– The benefits of <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">desmopressin</a> (DDAVP) to treat bleeding or to reduce the risk of bleeding in patients with reduced glomerular filtration rate (GFR) are uncertain. DDAVP may be used to treat or prevent bleeding on a case-by-case basis after weighing the potential risks of therapy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Some experts use DDAVP prior to surgery or invasive procedures in patients on chronic dialysis who have a history of excessive bleeding or who are not optimally dialyzed before surgery. DDAVP has also been used in individuals with chronic kidney disease (CKD) who are taking antiplatelet agents and require a procedure [<a href="#rid44">44</a>]. (See <a class="local">'Other measures'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Some experts use DDAVP in patients with acute bleeding. (See <a class="local">'Acute life-threatening bleeding'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing and monitoring</strong> – DDAVP dosing is the same whether used for prevention or treatment of bleeding. The dose is 0.3 mcg/kg intravenously or subcutaneously (intravenous [IV] administration is preferred for treatment of bleeding). For IV administration, DDAVP is given in 50 mL of <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> over 15 to 30 minutes. If administered preoperatively, it should be given 30 to 60 minutes prior to the procedure. Dosing can be repeated after 12 hours or once daily, but tachyphylaxis occurs after the first two or three doses, and therapy is generally not extended beyond one to two days. </p><p></p><p class="bulletIndent1">Efficacy is monitored clinically; there is no laboratory test that can be used to determine benefit. The putative effect is expected to occur within one hour of administration and last for four to eight hours. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risks</strong> – Risks of DDAVP include increased blood pressure, thrombosis, and hyponatremia, especially if free water intake is increased [<a href="#rid45">45-48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supporting evidence</strong> – No convincing data have demonstrated that DDAVP reduces the risk of clinically important bleeding associated with invasive procedures in patients with severely reduced GFR. Most supporting data for DDAVP are limited to observational studies, including small studies demonstrating reduced bleeding times in patients with uremic platelet dysfunction [<a href="#rid38">38,49</a>]. Bleeding time is a surrogate for bleeding risk that has not been validated in trials of clinically important bleeding. DDAVP is commonly used in von Willebrand disease for minor bleeding and minor procedures. (See  <a class="medical medical_review" href="/z/d/html/122618.html" rel="external">"von Willebrand disease (VWD): Treatment of minor bleeding, use of DDAVP, and routine preventive care", section on 'DDAVP'</a>.)</p><p></p><p class="headingAnchor" id="H4214368535"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110749.html" rel="external">"Society guideline links: Chronic kidney disease in adults"</a>.)</p><p class="headingAnchor" id="H17758614"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles</strong> – Bleeding associated with kidney disease can have many causes. Platelet dysfunction is thought to be the main determinant of abnormal bleeding in patients with severely reduced glomerular filtration rate (GFR). (See <a class="local">'Introduction'</a> above and <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Common bleeding sites include skin, mucosal (especially gastrointestinal [GI] tract), and intracerebral. There is no readily available assay that indicates bleeding is due to kidney function impairment. Platelet count, prothrombin time (PT), and activated partial thromboplastin time (aPTT) are unaffected by lower GFR. Platelet aggregation studies and bleeding time may be abnormal but are rarely performed. (See <a class="local">'Typical sites of bleeding'</a> above and <a class="local">'Laboratory findings'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk assessment</strong> – There is no specific cutoff for blood urea nitrogen (BUN) or serum creatinine that separates higher from lower bleeding risk. We consider patients who meet any of the following criteria to be at high risk for uremic platelet dysfunction (see <a class="local">'Assessment of bleeding risk'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>On dialysis</p><p class="bulletIndent2"><span class="glyph">•</span>Estimated GFR &lt;15 mL/min/1.73 m<sup>2</sup></p><p class="bulletIndent2"><span class="glyph">•</span>Oligoanuric acute kidney injury</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of bleeding</strong> – The primary goal is to identify and address the bleeding source. Despite the lack of high-quality evidence demonstrating benefit in this setting, <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">desmopressin</a> (DDAVP), platelet transfusion, Cryoprecipitate, and estrogen are sometimes used in certain clinical scenarios. (See <a class="local">'Acute life-threatening bleeding'</a> above and <a class="local">'Chronic refractory GI bleeding: Estrogens'</a> above and <a class="local">'Details of DDAVP administration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention of bleeding </strong>–<strong> </strong>In patients with severely reduced GFR who are undergoing a high-risk invasive procedure  (<a class="graphic graphic_table graphicRef86929" href="/z/d/graphic/86929.html" rel="external">table 2</a>), options that may reduce bleeding risk include therapy for anemia, DDAVP, and dialysis. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Anemia</strong> – For patients at high risk for uremic platelet dysfunction (see <a class="local">'Assessment of bleeding risk'</a> above) who are undergoing an urgent high-risk invasive procedure, are not planning to pursue kidney transplant, and have hemoglobin &lt;9 g/dL, we suggest red blood cell (RBC) transfusion targeted to raise the hemoglobin level to approximately 10 g/dL (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). </p><p></p><p class="bulletIndent2">For patients who are planning to undergo elective, high-risk invasive procedures, the hemoglobin is raised to approximately 10 g/dL with a recombinant erythropoiesis-stimulating agent (ESA) and/or iron (See <a class="local">'Treatment of anemia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>DDAVP</strong> – The benefit of periprocedural DDAVP to prevent uremic bleeding is uncertain. Some experts use DDAVP preoperatively or prior to an invasive procedure in patients on chronic dialysis who have a history of excessive bleeding or who are not optimally dialyzed before surgery. (See <a class="local">'Other measures'</a> above and <a class="local">'Details of DDAVP administration'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dialysis</strong> – It is unknown whether dialysis decreases the risk of uremic bleeding. In general, the use of dialysis solely to reduce the risk of bleeding is limited to patients who are inadequately dialyzed or to patients with severely reduced GFR who are planning to initiate dialysis. (See <a class="local">'Other measures'</a> above.)</p><p></p><p class="headingAnchor" id="H2276439328"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate would like to acknowledge Steven Coutre, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Morgagni GB. Opera Omnia. Ex Typographia Remondiniana. Venezia, Italy, 1764.</li><li><a class="nounderline abstract_t">Noris M, Remuzzi G. Uremic bleeding: closing the circle after 30 years of controversies? Blood 1999; 94:2569.</a></li><li><a class="nounderline abstract_t">Escolar G, Cases A, Bastida E, et al. Uremic platelets have a functional defect affecting the interaction of von Willebrand factor with glycoprotein IIb-IIIa. Blood 1990; 76:1336.</a></li><li><a class="nounderline abstract_t">Gawaz MP, Dobos G, Späth M, et al. Impaired function of platelet membrane glycoprotein IIb-IIIa in end-stage renal disease. J Am Soc Nephrol 1994; 5:36.</a></li><li><a class="nounderline abstract_t">Benigni A, Boccardo P, Galbusera M, et al. Reversible activation defect of the platelet glycoprotein IIb-IIIa complex in patients with uremia. Am J Kidney Dis 1993; 22:668.</a></li><li><a class="nounderline abstract_t">Di Minno G, Martinez J, McKean ML, et al. Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis. Am J Med 1985; 79:552.</a></li><li><a class="nounderline abstract_t">Kaw D, Malhotra D. Platelet dysfunction and end-stage renal disease. Semin Dial 2006; 19:317.</a></li><li><a class="nounderline abstract_t">Gonzalez J, Bryant S, Hermes-DeSantis ER. Transdermal estradiol for the management of refractory uremic bleeding. Am J Health Syst Pharm 2018; 75:e177.</a></li><li><a class="nounderline abstract_t">Evans EP, Branch RA, Bloom AL. A clinical and experimental study of platelet function in chronic renal failure. J Clin Pathol 1972; 25:745.</a></li><li><a class="nounderline abstract_t">Moia M, Mannucci PM, Vizzotto L, et al. Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin. Lancet 1987; 2:1227.</a></li><li><a class="nounderline abstract_t">Cases A, Escolar G, Reverter JC, et al. Recombinant human erythropoietin treatment improves platelet function in uremic patients. Kidney Int 1992; 42:668.</a></li><li><a class="nounderline abstract_t">Gaspari F, Viganò G, Orisio S, et al. Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclooxygenase inhibition. J Clin Invest 1987; 79:1788.</a></li><li><a class="nounderline abstract_t">Hedges SJ, Dehoney SB, Hooper JS, et al. Evidence-based treatment recommendations for uremic bleeding. Nat Clin Pract Nephrol 2007; 3:138.</a></li><li><a class="nounderline abstract_t">Galbusera M, Remuzzi G, Boccardo P. Treatment of bleeding in dialysis patients. Semin Dial 2009; 22:279.</a></li><li><a class="nounderline abstract_t">Steiner RW, Coggins C, Carvalho AC. Bleeding time in uremia: a useful test to assess clinical bleeding. Am J Hematol 1979; 7:107.</a></li><li><a class="nounderline abstract_t">Molnar AO, Bota SE, Garg AX, et al. The Risk of Major Hemorrhage with CKD. J Am Soc Nephrol 2016; 27:2825.</a></li><li><a class="nounderline abstract_t">Mahady SE, Polekhina G, Woods RL, et al. Association Between CKD and Major Hemorrhage in Older Persons: Data From the Aspirin in Reducing Events in the Elderly Randomized Trial. Kidney Int Rep 2023; 8:737.</a></li><li><a class="nounderline abstract_t">Sood MM, Bota SE, McArthur E, et al. The three-year incidence of major hemorrhage among older adults initiating chronic dialysis. Can J Kidney Health Dis 2014; 1:21.</a></li><li><a class="nounderline abstract_t">RATH CE, MAILLIARD JA, SCHREINER GE. Bleeding tendency in uremia. N Engl J Med 1957; 257:808.</a></li><li><a class="nounderline abstract_t">FERGUSON JH, LEWIS JH, ZUCKER MB. Bleeding tendency in uremia. Blood 1956; 11:1073.</a></li><li><a class="nounderline abstract_t">Molino D, De Lucia D, Gaspare De Santo N. Coagulation disorders in uremia. Semin Nephrol 2006; 26:46.</a></li><li><a class="nounderline abstract_t">Vanent KN, Leasure AC, Acosta JN, et al. Association of Chronic Kidney Disease With Risk of Intracerebral Hemorrhage. JAMA Neurol 2022; 79:911.</a></li><li><a class="nounderline abstract_t">Maejima M, Takahashi S, Hatano M. [Platelet aggregation in chronic renal failure--whole blood aggregation and effect of guanidino compounds]. Nihon Jinzo Gakkai Shi 1991; 33:201.</a></li><li><a class="nounderline abstract_t">Escolar G, Díaz-Ricart M, Cases A. Uremic platelet dysfunction: past and present. Curr Hematol Rep 2005; 4:359.</a></li><li><a class="nounderline abstract_t">Lee HK, Kim YJ, Jeong JU, et al. Desmopressin improves platelet dysfunction measured by in vitro closure time in uremic patients. Nephron Clin Pract 2010; 114:c248.</a></li><li><a class="nounderline abstract_t">Waki K, Hayashi A, Ikeda S, et al. Measuring platelet aggregation in dialysis patients with a whole blood aggregometer by the screen filtration pressure method. Ther Apher Dial 2011; 15:203.</a></li><li><a class="nounderline abstract_t">Zeck J, Schallheim J, Lew SQ, DePalma L. Whole blood platelet aggregation and release reaction testing in uremic patients. Biomed Res Int 2013; 2013:486290.</a></li><li><a class="nounderline abstract_t">Marques M, Sacristán D, Mateos-Cáceres PJ, et al. Different protein expression in normal and dysfunctional platelets from uremic patients. J Nephrol 2010; 23:90.</a></li><li><a class="nounderline abstract_t">Janson PA, Jubelirer SJ, Weinstein MJ, Deykin D. Treatment of the bleeding tendency in uremia with cryoprecipitate. N Engl J Med 1980; 303:1318.</a></li><li><a class="nounderline abstract_t">Triulzi DJ, Blumberg N. Variability in response to cryoprecipitate treatment for hemostatic defects in uremia. Yale J Biol Med 1990; 63:1.</a></li><li><a class="nounderline abstract_t">Livio M, Mannucci PM, Viganò G, et al. Conjugated estrogens for the management of bleeding associated with renal failure. N Engl J Med 1986; 315:731.</a></li><li><a class="nounderline abstract_t">Heistinger M, Stockenhuber F, Schneider B, et al. Effect of conjugated estrogens on platelet function and prostacyclin generation in CRF. Kidney Int 1990; 38:1181.</a></li><li><a class="nounderline abstract_t">Viganò G, Gaspari F, Locatelli M, et al. Dose-effect and pharmacokinetics of estrogens given to correct bleeding time in uremia. Kidney Int 1988; 34:853.</a></li><li><a class="nounderline abstract_t">Sloand JA, Schiff MJ. Beneficial effect of low-dose transdermal estrogen on bleeding time and clinical bleeding in uremia. Am J Kidney Dis 1995; 26:22.</a></li><li><a class="nounderline abstract_t">Bronner MH, Pate MB, Cunningham JT, Marsh WH. Estrogen-progesterone therapy for bleeding gastrointestinal telangiectasias in chronic renal failure. An uncontrolled trial. Ann Intern Med 1986; 105:371.</a></li><li><a class="nounderline abstract_t">Shemin D, Elnour M, Amarantes B, et al. Oral estrogens decrease bleeding time and improve clinical bleeding in patients with renal failure. Am J Med 1990; 89:436.</a></li><li><a class="nounderline abstract_t">Livio M, Gotti E, Marchesi D, et al. Uraemic bleeding: role of anaemia and beneficial effect of red cell transfusions. Lancet 1982; 2:1013.</a></li><li><a class="nounderline abstract_t">Mannucci PM, Remuzzi G, Pusineri F, et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 1983; 308:8.</a></li><li><a class="nounderline abstract_t">Mannucci PM. Hemostatic drugs. N Engl J Med 1998; 339:245.</a></li><li><a class="nounderline abstract_t">Sidawy AN, Spergel LM, Besarab A, et al. The Society for Vascular Surgery: clinical practice guidelines for the surgical placement and maintenance of arteriovenous hemodialysis access. J Vasc Surg 2008; 48:2S.</a></li><li><a class="nounderline abstract_t">Stewart JH, Castaldi PA. Uraemic bleeding: a reversible platelet defect corrected by dialysis. Q J Med 1967; 36:409.</a></li><li><a class="nounderline abstract_t">Nenci GG, Berrettini M, Agnelli G, et al. Effect of peritoneal dialysis, haemodialysis and kidney transplantation on blood platelet function. I. Platelet aggregation by ADP and epinephrine. Nephron 1979; 23:287.</a></li><li><a class="nounderline abstract_t">Lindsay RM, Friesen M, Aronstam A, et al. Improvement of platelet function by increased frequency of hemodialysis. Clin Nephrol 1978; 10:67.</a></li><li><a class="nounderline abstract_t">Kim JH, Baek CH, Min JY, et al. Desmopressin improves platelet function in uremic patients taking antiplatelet agents who require emergent invasive procedures. Ann Hematol 2015; 94:1457.</a></li><li><a class="nounderline abstract_t">Byrnes JJ, Larcada A, Moake JL. Thrombosis following desmopressin for uremic bleeding. Am J Hematol 1988; 28:63.</a></li><li><a class="nounderline abstract_t">Whittier WL. Percutaneous kidney biopsy: "the needle and the damage done"? Am J Kidney Dis 2011; 57:808.</a></li><li><a class="nounderline abstract_t">Lees JS, McQuarrie EP, Mackinnon B. Renal biopsy: it is time for pragmatism and consensus. Clin Kidney J 2018; 11:605.</a></li><li><a class="nounderline abstract_t">Lim CC, Siow B, Choo JCJ, et al. Desmopressin for the prevention of bleeding in percutaneous kidney biopsy: efficacy and hyponatremia. Int Urol Nephrol 2019; 51:995.</a></li><li><a class="nounderline abstract_t">Zeigler ZR, Megaludis A, Fraley DS. Desmopressin (d-DAVP) effects on platelet rheology and von Willebrand factor activities in uremia. Am J Hematol 1992; 39:90.</a></li></ol></div><div id="topicVersionRevision">Topic 1947 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Morgagni GB. Opera Omnia. Ex Typographia Remondiniana. Venezia, Italy, 1764.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10515859" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Uremic bleeding: closing the circle after 30 years of controversies?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2207311" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Uremic platelets have a functional defect affecting the interaction of von Willebrand factor with glycoprotein IIb-IIIa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7524718" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Impaired function of platelet membrane glycoprotein IIb-IIIa in end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8238012" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Reversible activation defect of the platelet glycoprotein IIb-IIIa complex in patients with uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3933340" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16893410" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Platelet dysfunction and end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29691259" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Transdermal estradiol for the management of refractory uremic bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5086216" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A clinical and experimental study of platelet function in chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2890852" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1405344" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Recombinant human erythropoietin treatment improves platelet function in uremic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3108321" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclooxygenase inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17322926" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Evidence-based treatment recommendations for uremic bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19573008" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Treatment of bleeding in dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/539588" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Bleeding time in uremia: a useful test to assess clinical bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26823554" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The Risk of Major Hemorrhage with CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37069989" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Association Between CKD and Major Hemorrhage in Older Persons: Data From the Aspirin in Reducing Events in the Elderly Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25780611" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The three-year incidence of major hemorrhage among older adults initiating chronic dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13477393" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Bleeding tendency in uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13373925" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Bleeding tendency in uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16412826" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Coagulation disorders in uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35969388" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Association of Chronic Kidney Disease With Risk of Intracerebral Hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2051648" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : [Platelet aggregation in chronic renal failure--whole blood aggregation and effect of guanidino compounds].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16131436" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Uremic platelet dysfunction: past and present.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20090366" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Desmopressin improves platelet dysfunction measured by in vitro closure time in uremic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21426514" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Measuring platelet aggregation in dialysis patients with a whole blood aggregometer by the screen filtration pressure method.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23878808" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Whole blood platelet aggregation and release reaction testing in uremic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20091492" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Different protein expression in normal and dysfunctional platelets from uremic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6776402" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Treatment of the bleeding tendency in uremia with cryoprecipitate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2113328" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Variability in response to cryoprecipitate treatment for hemostatic defects in uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3018561" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Conjugated estrogens for the management of bleeding associated with renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1963650" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effect of conjugated estrogens on platelet function and prostacyclin generation in CRF.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2850395" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Dose-effect and pharmacokinetics of estrogens given to correct bleeding time in uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7611255" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Beneficial effect of low-dose transdermal estrogen on bleeding time and clinical bleeding in uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3488703" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Estrogen-progesterone therapy for bleeding gastrointestinal telangiectasias in chronic renal failure. An uncontrolled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2171332" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Oral estrogens decrease bleeding time and improve clinical bleeding in patients with renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6127502" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Uraemic bleeding: role of anaemia and beneficial effect of red cell transfusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6401193" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9673304" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Hemostatic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19000589" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The Society for Vascular Surgery: clinical practice guidelines for the surgical placement and maintenance of arteriovenous hemodialysis access.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4860589" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Uraemic bleeding: a reversible platelet defect corrected by dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/384281" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Effect of peritoneal dialysis, haemodialysis and kidney transplantation on blood platelet function. I. Platelet aggregation by ADP and epinephrine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/699401" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Improvement of platelet function by increased frequency of hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25933676" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Desmopressin improves platelet function in uremic patients taking antiplatelet agents who require emergent invasive procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3259400" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Thrombosis following desmopressin for uremic bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21601125" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Percutaneous kidney biopsy: "the needle and the damage done"?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30289128" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Renal biopsy: it is time for pragmatism and consensus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31028561" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Desmopressin for the prevention of bleeding in percutaneous kidney biopsy: efficacy and hyponatremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1550112" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Desmopressin (d-DAVP) effects on platelet rheology and von Willebrand factor activities in uremia.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
